TABLE 3.
Pooled results from the treatment safety of included studies
Side effects n (%) |
Intervention n (%) | Discontinuation n (%) |
Adverse events n (%) |
|
---|---|---|---|---|
Reduction of immunosuppressive medication (21 studies, 174 patients) | 3 (2) | 3 (2) | NA | 2 (1) |
Ribavirin (34 studies, 395 patients) | 122 (31) | 142 (36) | 8 (2) | 4 (1) |
Pegylated interferon‐α (8 studies, 13 patients) | 5 (38) | 5 (38) | 2 (15) | 2 (15) |